Sep 26, 2019
GT Biopharma Announces HIV Trike(TM) Data to be Published
Sep 09, 2019
NKMax America Announces New cGMP Manufacturing Facility for Production of SNK Cell Therapy
Sep 09, 2019
Juntendo University Research: IPS Based Approach for Treating Virus-induced Tumors
Aug 20, 2019
NKMax America Initiates Phase I Clinical Trial of SNK in Patients with Psoriasis in Mexico
Aug 15, 2019
Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics
Aug 13, 2019
NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer
Aug 02, 2019
Study Reveals How 'Natural-Killer' Cells Might Help Women Avoid a Deadly Risk of Childbirth
Jul 29, 2019
Natural Killer (NK) Cell Therapeutics Market to Reach $5.09 Bn, Globally, by 2026, at 17.4% CAGR: Allied Market Research
Jul 24, 2019
Natural Killer Cell Therapies Pipeline Review 2019
Jun 10, 2019
GT Biopharma Company Update
Apr 29, 2019
University of Minnesota research team works to eradicate HIV with natural killer cells
Apr 24, 2019
GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
Apr 16, 2019
Key Patent Issued for Xyphos Biosciences' ACCEL(TM) Technology Platform
Apr 02, 2019
Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects
Feb 01, 2019
Cell Surface Markers - Worldwide Market Analysis & Outlook (2018-2023): The Increasing Funding for Life Science Research is Driving Market Growth
Jan 28, 2019
UMN Medical School Researchers Discover New Therapy for Prostate Cancer Patients
Jan 23, 2019
B-MoGen Biotechnologies and CytoSen Therapeutics partner on research collaboration to develop next generation Natural Killer Cells for human therapeutics
Oct 18, 2018
The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment
Sep 26, 2018
RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference
Aug 30, 2018
GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration